following a full submission:
fezolinetant (Veoza®) is not recommended for use within NHSScotland.
Indication under review: for the treatment of moderate to severe vasomotor symptoms
(VMS) associated with menopause.
In a phase IIIb study fezolinetant significantly reduced the frequency of VMS in menopausal
participants considered unsuitable for hormone therapy compared with placebo. In addition,
in two identical phase III studies fezolinetant significantly reduced the frequency and
severity of VMS compared with placebo in menopausal participants.
The submitting company did not present a sufficiently robust economic analysis to gain
acceptance by SMC.
The submitting company has indicated their intention to make a resubmission.
Medicine details
- Medicine name:
- fezolinetant (Veoza)
- SMC ID:
- SMC2798
- Indication:
For the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
- Pharmaceutical company
- Astellas Pharma Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 07 July 2025